Michael S. Cuoco

Broad Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index8.4kcitations78works12.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibroblast Growth Factor Research(28), Metastasis and carcinoma case studies(22), Cancer Cells and Metastasis(18), Single-cell and spatial transcriptomics(18), Cancer Genomics and Diagnostics(14)

Publications78 total

Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and <i>BAP1</i> loss
Science Advances·2026Open Access
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Cancer Cell·2025· 3 citedOpen Access
Single-cell epigenetic profiling reveals an interferon response-high program associated with <i>BAP1</i> deficiency in kidney cancer
2024· 4 citedOpen Access
Protective role for kidney TREM2 macrophages in obesity- and diabetes-induced kidney injury
Cell Reports·2024· 33 citedOpen Access
Long interspersed nuclear elements safeguard neural progenitors from precocious differentiation
Cell Reports·2024· 20 citedOpen Access
Junior scientists spotlight social bonds in seminars for diversity, equity, and inclusion in STEM
PLoS ONE·2023· 1 citedOpen Access
Cancer aneuploidies are shaped primarily by effects on tumour fitness
Nature·2023· 101 citedOpen Access
Structural and functional properties of mSWI/SNF chromatin remodeling complexes revealed through single-cell perturbation screens
Molecular Cell·2023· 41 citedOpen Access
Supplemental Table 3 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 5 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 12 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 4 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 13 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 9 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 4 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 13 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 11 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 8 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 2 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
Supplemental Table 7 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER&lt;sup&gt;+&lt;/sup&gt; Metastatic Breast Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Aviv Regev(38), Orit Rozenblatt–Rosen(28), Danielle Dionne(13), Julia Waldman(11), Ofir Cohen(11), Asaf Rotem(10), Benjamin Izar(10), Nikhil Wagle(10), Lan Nguyễn(9), Christopher Rodman(8), Abhay Kanodia(8), Orr Ashenberg(8), Sébastien Vigneau(8), Michal Slyper(8), Jorge E. Buendia-Buendia(8), Livnat Jerby‐Arnon(7), Ayshwarya Subramanian(7), Utthara Nayar(7), Adrienne G. Waks(7), Seth A. Wander(7)